In a nutshell This study outlines the ESMO guidelines for the diagnosis, treatment and follow-up of Hodgkin lymphoma. Some background Hodgkin lymphoma is a cancer of the lymph system. It mostly occurs in young adults, but can also occur in adults over the age of 55. The European Society for Medical Oncology (ESMO) has recently updated their...
Read More
In a nutshell This study reviewed the treatment options for early-stage Hodgkin lymphoma. Some background Early-stage Hodgkin lymphoma refers to stages I and II. Early-stage can be further divided into favorable or unfavorable. Patients with unfavorable disease may present with certain risk factors. These include large chest tumors, inflammation...
Read More
In a nutshell This review outlines the treatment options for Hodgkin lymphoma that has relapsed or that did not respond to treatment. Some background Standard treatment for Hodgkin lymphoma is a combination of chemotherapy and radiation. More than 80% of patients achieve long-term cure with these treatments. Some patients do not respond to...
Read MoreIn a nutshell This study aimed to determine whether chemotherapy and radiation doses can be reduced in early-stage favorable Hodgkin lymphoma treatment. This study concluded that fewer chemotherapy cycles and a lower dose of radiation was effective in patients with a good prognosis. Some background Radiation was the original standard...
Read More
In a nutshell This study examined the use of nivolumab (Opdivo) in patients with heavily pretreated Hodgkin lymphoma. The authors concluded that nivolumab was effective and safe in these patients. Some background PD-1 is a protein that slows the immune response. Many cancer cells use the PD-1 pathway to block the immune system from attacking...
Read More
In a nutshell This review discussed the current and future treatment options for advanced Hodgkin lymphoma (stage III or IV). Some background While early-stage Hodgkin lymphoma has very high remission rates, rates for advanced disease are generally lower. The standard treatment option for advanced Hodgkin lymphoma is ABVD chemotherapy...
Read More
In a nutshell The current study examined the safety and effectiveness of the chemotherapy combination ABVD in early-stage Hodgkin lymphoma patients over the age of 60. This study concluded that the standard four cycles of ABVD led to increased need for dose reduction and increased negative effects in older patients. Some background While the...
Read More
In a nutshell This trial examined the longer-term effectiveness of brentuximab vedotin (Adcetris) after stem cell transplant in patients with relapsed or refractory (did not respond to treatment) Hodgkin lymphoma. The authors concluded that patients who respond to brentuximab vedotin can achieve long-term disease control. Some background...
Read More
In a nutshell This study examined whether the number of chemotherapy agents in the combination ABVD could be reduced when treating Hodgkin lymphoma. The authors concluded that to be effective all four chemotherapies need to be included. Some background More than 80% of patients with early-stage, favorable Hodgkin lymphoma experience long-term...
Read More
In a nutshell This trial compared the safety and effectiveness of treatment with ABVD chemotherapy with or without radiation and radiation alone in patients with early-stage (stage I or II) Hodgkin lymphoma. The authors concluded that ABVD alone was associated with a higher overall survival (time from treatment until death due to any cause) rate. This...
Read More
In a nutshell This study examined the safety and effectiveness of ABVD chemotherapy in older patients with Hodgkin lymphoma. The study concluded that ABVD was effective in older patients, but may need some modifications. Some background Roughly 20% of Hodgkin lymphoma patients are over the age of 60. Older patients are treated with the same...
Read More
In a nutshell This study reviewed recommendations for the staging and treatment of Hodgkin lymphoma. Some background Current treatment options for Hodgkin lymphoma have led to a cure rate of 80%. Radiation with or without chemotherapy has become the standard treatment. These treatments, however, can lead to long-term negative effects, such as...
Read More
